Insights

5G architecture will be like nothing seen before, combining terrestrial and non-terrestrial networks (NTNs) – including high-altitude platforms and low earth orbit satellites. 

This paper explores the emerging technology that will unlock the full potential of NTNs and examines the commercial opportunities, which will create value for everyone in the ecosystem.  

Private 5G networks promise to deliver huge business advantage. But, where to start if you are an enterprise, carrier or technology supplier considering deployment? This whitepaper is a practical guide to deploying a private 5G network for maximum business impact, including when using CBRS spectrum in the United States.

In this whitepaper we examine the potential rewards of sustainable yet multidimensional business growth and reveal why whole system mapping is a prerequisite for driving essential system-level – not just product-level – innovation.

The changing regulatory and subsidy systems underpinning farming are undergoing radical change. Furthermore, issues such as soil health, net zero and farm nature value are increasingly in the public eye.

Watch our webinar to discover how deep learning is allowing us to design optimized protein sequences to perform beyond those found in nature.

5G is a game-changer in mobile broadband services – and not only in terms of data speeds and low latencies. 5G will be the first architecture to combine terrestrial networks and non-terrestrial platforms (NTNs) such as HAPs and LEO satellite constellations – into a hybrid network, providing truly ubiquitous mobile broadband and exciting new revenue opportunities across the ecosystem.

Scale-down models have become a popular development tool, especially in the bioprocessing industry. But how do you make them robust and reproducible?

Winning a prestigious international design award for our product innovation here at Cambridge Consultants is obviously fantastic – so scooping not just one but four gongs in the coveted iF Design Awards is great for everyone involved. Andy Pigeon, our head of User centred Design reviews the four winners.

Scale-down models have become an increasingly common development tool, especially in the bioprocessing industry. Read our eBook to discover our approach to the challenge of scaling up scale down models.

The number of effective cell and gene therapies is growing rapidly, especially for treating ocular diseases. However, much less attention has been focused on the critical issue of delivery to the eye. 

The hugely exciting – not to say revolutionary – promise of quantum computing comes with a significant challenge. The seismic technology shift that is already underway will render a chunk of our current cryptographic standards moot. 

If you’re a surgical robotics start-up, the timing of your risk assessment will determine the level of success you achieve. Andrew Savarese, VP, Surgical Robotics & Advanced Surgical Systems, delves into his deep experience and comes up with crucial advice to make sure you spend the right money once, not the wrong money twice.